Acute Lymphoblastic Leukemia All clinical trials

Explore recruiting acute lymphoblastic leukemia all clinical trials.

Recruiting acute lymphoblastic leukemia all studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Lymphoblastic Leukemia All trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia

Netherlands, Austria, Czechia, Denmark, Finland, Hungary +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

Netherlands, Czechia, Italy, Spain, Denmark, Austria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

B1931036 - A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH- RISK OR VERY HIGH-RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA

Sweden, Norway, Greece, Finland, Austria, Poland +10 more

Therapeutic exploratory (Phase II) EU CTIS Study details

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group – IntReALL HR 2010

Czechia, Spain, Belgium, Netherlands, France, Germany +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Acute Lymphoblastic Leukemia All trials by city

Acute Lymphoblastic Leukemia All clinical trials

Recruiting acute lymphoblastic leukemia all studies right now

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Orphan Indications for CD19 Redirected Autologous T Cells

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Also recruiting in Europe

CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents

Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

B1931036 - A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH- RISK OR VERY HIGH-RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA

International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group – IntReALL HR 2010

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

Acute Lymphoblastic Leukemia All trials by city

Other conditions